[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-lesions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-lesions":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,81,112,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100633228","paraffin-oil-for-preventing-tourniquet-related-skin-lesions-in-upper-extremity-surgery-100633228",false,"NCT07523958","Paraffin Oil for Preventing Tourniquet-Related Skin Lesions in Upper Extremity Surgery","Paraffin Oil for Preventing Tourniquet-Related Skin Lesions in Upper Extremity Surgery (PARA-TOUR RCT)","PARA-TOUR","IInclusion Criteria:\n\n* Age ≥18 years\n* Patients scheduled for elective upper extremity surgery requiring pneumatic tourniquet application\n* ASA physical status I-III\n* Body mass index (BMI) \\\u003C30 kg\u002Fm²\n* Ability to provide informed consent\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Known dermatological disease or existing skin lesion at the tourniquet application site\n* Allergy or sensitivity to paraffin oil or related substances\n* Severe systemic disease (ASA IV or higher)\n* Obesity (BMI ≥30 kg\u002Fm²)\n* Emergency surgery\n* Patients transferred to intensive care postoperatively\n* Development of major postoperative complications (e.g., hematoma, seroma, nerve injury, significant bleeding)\n* Inability to communicate or comply with study procedures\n* Withdrawal from the study at any time","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial aims to evaluate the effectiveness of topical paraffin oil application in preventing tourniquet-related skin lesions in patients undergoing upper extremity surgery. Pneumatic tourniquets are commonly used to provide a bloodless surgical field; however, they may cause skin complications such as erythema, edema, abrasions, blisters, and burns.\n\nIn this study, adult patients undergoing elective upper extremity surgery will be randomly assigned to either an intervention group receiving topical paraffin oil application in addition to routine protective dressing or a control group receiving routine care only. Skin integrity will be assessed immediately after tourniquet removal and at 30 and 60 minutes postoperatively using standardized skin assessment criteria.\n\nThe findings of this study are expected to contribute to the development of effective, simple, and cost-efficient strategies to prevent tourniquet-related skin complications and improve patient safety and postoperative comfort.",[27,28,29],"Pressure Injury","Skin Lesions","Skin Injury",[31,32,33,34,35],"Paraffin Oil","Tourniquet","Upper Extremity Surgery","Skin Injury Prevention","Randomized Controlled Trial","RECRUITING","2026-06-02",{"date":39,"type":40},"2026-06-04","ACTUAL",{"date":42,"type":40},"2026-01-12",{"date":44,"type":21},"2026-07",{"name":46,"class":47},"Istanbul Medipol University Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":5},"100619847","early-detection-of-skin-tumors-using-a-telemedicine-tool-in-primary-care-100619847","NCT07349940","Early Detection of Skin Tumors Using a Telemedicine Tool in Primary Care","MEL","Inclusion Criteria:\n\n* at least 1 suspected lession\n* phototype I or phototype II\n\nExclusion Criteria:\n\n* skin lession examination by dermatologist in last 12 months\n* unsigned consent to participate in the project and consent to the processing of personal data","50 Years",{"count":58,"type":21},1440,[24],"The project is a national, prospective, multicenter, single-arm interventional pilot of screening skin tumors in the Czech Republic.\n\nThe primary aim of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of skin tumors by using a telemedicine tools and setting up and testing new methods and implementation into the system of social health care.",[62,63,28,64,65],"Skin Cancer Prevention","Melanoma In Situ","Skin Cancer","Mole (Dermatology)",[67,68,69,70],"skin cancer","melanoma","telemedicine tool","skin tumors","2026-03-25",{"date":73,"type":40},"2026-03-27",{"date":75,"type":40},"2026-02-01",{"date":77,"type":21},"2026-09-30",{"name":79,"class":80},"Institute of Health Information and Statistics of the Czech Republic","OTHER_GOV",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100628954","human-ai-uncertainty-callibration-for-improved-skin-lesion-segmentation-100628954","NCT07468357","Human-AI Uncertainty Callibration for Improved Skin Lesion Segmentation","The Effect of Human-AI Uncertainty Calibration vs. AI Uncertainty Alone on the Diagnostic Accuracy of Human Experts for Skin Lesions - a Randomized Controlled Trial.","Inclusion Criteria:\n\n* Board certified dermatologists with clinical experience in dermoscopic diagnosis.\n\nExclusion Criteria:\n\n* Doctors who have not yet finished their specialization and dermatologists.\n* Dermatologists without clinical experience in dermoscopic diagnosis.",true,{"count":90,"type":21},50,[24],"The goal of this randomized controlled study is to compare the effect of a new, personalized uncertainty-aware decision model (FDM) to a standard image recognition model in improving the diagnostic accuracy while reducing diagnostic uncertainty in experienced dermatologists tasked with differentiating between melanomas, moles and other benign skin lesions. The main question it aims to answer: Is the FDM a feasible method for an improved human AI partnership in which trust is build, misdiagnoses are avoided, and uncertainty is duly introduced or reduced.\n\nThe investigators expect to see only a slight increase in collective diagnostic accuracy for both interventions as the the human participants are skilled dermatologist and thus have high accuracies pre-intervention.\n\nThe investigators expect to see a higher increase in diagnostic certainty for the FDM intervention compared to the diagnostic certainty in the Base Model intervention.\n\nThe investigators expect to see a higher amount of diagnosis changes from incorrect to correct in the FDM group compared to the Base Model group.\n\nThe investigators do not expect any learning effect during the study.\n\nParticipants will start by answering a series of training cases consisting of images of skin lesions. These are used to train their individual FDM (only for the FDM-intervention group). From here, the participants will be randomized into two arms determining which of the two interventions they are exposed to. The participants will solve each case withouth any intervention first, and this reply will act as a control.",[28],[95,96,97,98,99,100,101],"Dermatology","AI","Artificial Intelligence","Uncertainty Calibration","Dermoscopy","Bayesian Deep Learning","Human-AI Decision Model","NOT_YET_RECRUITING","2026-03-11",{"date":105,"type":40},"2026-03-12",{"date":107,"type":21},"2026-03-01",{"date":109,"type":21},"2026-11",{"name":111,"class":47},"Copenhagen Academy for Medical Education and Simulation",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100579415","phase-4-prevention-and-treatment-for-bruises-in-patients-with-ischemic-stroke-100579415","NCT06823999","Prevention and Treatment for Bruises in Patients With Ischemic Stroke","Effect of Vitamin C in the Prevention and Treatment for Bruises in Patients With Ischemic Stroke: A Double-blind Randomized Control Trial","Inclusion Criteria:\n\n* Ischemic stroke patients.\n* Aged 20 to 85 years.\n\nExclusion Criteria:\n\n* o Cancer patients undergoing chemotherapy.\n\n  * End-stage renal disease patients receiving hemodialysis.\n  * Patients undergoing immunosuppressive therapy.\n  * Patients with coagulation disorders.\n  * Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (favism).\n  * Patients with thalassemia.\n  * Patients who did not sign the consent form.","20 Years","85 Years",{"count":122,"type":21},400,[124],"PHASE4","Background Over the past few decades, significant advances have been made in the diagnosis and treatment of strokes. Most studies focus on functional recovery in stroke patients. In addition to motor function, there are many symptoms may affect function and quality of life in stroke patients. Bruises are caused by damage to the skin that causes blood to drain out of the capillaries and accumulate in the connective tissue of the skin or subcutaneous tissue. The study on non-motor syndrome in ischemic stroke patients found that 25.8% of ischemic stroke patients had bruises and 17.7% of bruises were unexplained bruises. In addition to the physiological and emotional effects on stroke patients, bruises may increase infection risk and affect stroke patient outcomes. Vitamin C is a natural antioxidant discovered in 1747 to treat and prevent scurvy. Vitamin C can reduce gum bleeding and prevent colon bleeding after a polypectomy. Vitamin C has been reported to reduce brain edema around brain injury and decrease mortality in patients with traumatic brain injury. Dehydroascorbic acid decreases infarct volume in mice with middle cerebral artery occlusion. Investigators hypothesized that administration of vitamin C to patients with acute ischemic stroke patients would decrease the risk of bleeding and enhance its resolution. Investigators also hypothesized that vitamin C injection could minimize infarct volume and improve outcomes in ischemic stroke patients. The aims of the study include: 1. To investigate whether vitamin C injections can reduce bruising risk and enhance bruising resolution. 2. To explore whether vitamin C injections in the acute phase of stroke can improve the prognosis of ischemic stroke patients.\n\nMethods This is a prospective, double-blind, randomized controlled study. All patients admitted to the hospital under the diagnosis of ischemic stroke and stroke was confirmed by Magnetic Resonance imaging (MRI) or brain computed imaging (CT) and aged between 20 and 85 years were invited to participate in the study. Investigators excluded patients who had these diseases: cancer receiving chemotherapy, end stage renal disease receiving dialysis, autoimmune disease, hematological disease, Glucose-6-phosphatase disease, gouty arthritis, and a lack of informed consent.\n\nDuring the study period, all patients who met the inclusion and exclusion criteria were invited to participate in the study. After informed consent, participants were randomly assigned to the experimental group or the control group. All participants underwent NIHSS evaluation and a detailed dermatological examination on the day of hospitalization. After enrollment, the experimental group received 4 mg Vitamin C injection per day for 4 days, while the control group received the same volume of normal saline injection per day for 4 days. Researchers evaluate participant skin condition (including bruises number and size, color) every day during hospitalization, and up to 1 month after stroke. Investigators evaluate NIHSS at discharge and follow-up functional outcome (mRS) up to 3 months after stroke onset.\n\nAnalysis Rate shows bruise percentage. Chi square or Fisher exact test was applied to compare the difference in bruises between two groups. Logistic regression was used to compare bruise risk between groups. Wilcoxon rank sign test was used to analyze stroke severity and outcome between two groups.",[127,128,28],"Stroke","Bruises",[130,131,132,133,134],"stroke","bruises","skin lesions","vitamin C","bleeding","2025-02-11",{"date":137,"type":40},"2025-02-13",{"date":139,"type":21},"2025-08-01",{"date":141,"type":21},"2028-07-31",{"name":143,"class":47},"Chiayi Christian Hospital",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":48},"100573913","evaluation-of-the-ef192b-protection-versus-no-treatment-100573913","NCT06752460","Evaluation of the EF192B Protection Versus No Treatment","Randomized, Open Clinical Study to Evaluate the Protective Potential of EF192B Versus No Treatment","Spray B","Inclusion criteria\n\n* Age between 18 and 70 years old.\n* Fitzpatrick skin phototype classification I to IV.\n* Presence of intact skin in the test region (right forearm and left forearm for selected participants).\n* Agreement to adhere to the study procedures and requirements and attend the institute on the days and times determined for the assessments.\n* Signing of the Informed Consent Form (ICF) and the Image Disclosure Consent Form (IDCF) before carrying out any study procedure.\n\nExclusion Criteria\n\n* Diagnosis of skin diseases such as vitiligo, psoriasis, atopic dermatitis.\n* Diagnosis of immunological insufficiency.\n* Use of systemic corticosteroids or immunosuppressants.\n* Diagnosis of type 1 diabetes mellitus or insulin-dependent diabetes or presence of complications resulting from diabetes (such as retinopathy, nephropathy, neuropathy), presence of diabetes-related dermatoses (such as plantar ulcers, lipoid necrobiosis, granuloma annulare, opportunistic infections), history of episodes of hypoglycemia, diabetic ketoacidosis and\u002For hyperosmolar coma.\n* History of reaction to liquid dressings.\n* Known hypersensitivity to any ingredients of investigational product formulation.\n* Other diseases or use of drugs that may directly interfere with the study or put the research participant's health at risk.\n* Presence of any serious or uncontrolled diseases, at the investigator's discretion.\n* Pregnancy or lactation.\n* Participation in a clinical research protocol in the last 12 months, unless, at the investigator's discretion, their participation in the study may result in direct benefit to the participant.\n* Presence of any conditions that, at the investigator's discretion, make the participant unable to participate in the study.","70 Years",{"count":154,"type":21},72,[24],"This study was designed with the objective of evaluating the protection potential provided by the experimental product EF192B by evaluating its barrier formation capacity. Once its ability to form a barrier is confirmed, EF192B ability to protect against small skin injuries, such as small cuts, bruises, blisters and cracks is confirmed. The barrier formation also guarantees protection against the formation of calluses.",[28,158],"Skin Care",[160,161],"effectiveness","Contact test","2024-12-20",{"date":164,"type":40},"2024-12-30",{"date":166,"type":21},"2025-08-31",{"date":168,"type":21},"2025-10-31",{"name":170,"class":171},"Eurofarma Laboratorios S.A.","INDUSTRY"]